Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
June 25, 2025 7:05 AM EDT
Sanofi to advance Kymeras next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile
Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,
and may opt-in to 50/50 development and profit share of KT-485 in the U.S.
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) --... More
June 25, 2025 7:00 AM EDT
FOSTER CITY, Calif. & WATERTOWN, Mass.--(BUSINESS WIRE)--
Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.
This press release features multimedia. View the full release here:... More
